UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup
2016 ◽
Vol 34
(6)
◽
pp. 521-523
◽
2015 ◽
Vol 33
(1)
◽
pp. 124-125
◽
2020 ◽
Vol Publish Ahead of Print
◽
2017 ◽
Vol 142
(4)
◽
pp. 844-853
◽